



OPEN ACCESS

APPROVED BY

Giuseppe Giaccone,
Cornell University, United States

*CORRESPONDENCE

Frontiers Editorial Office
research.integrity@frontiersin.org

SPECIALTY SECTION

This article was submitted to
Molecular and Cellular Oncology,
a section of the journal
Frontiers in Oncology

RECEIVED 15 September 2022

ACCEPTED 15 September 2022

PUBLISHED 27 September 2022

CITATION

Frontiers Editorial Office (2022)
Retraction: A novel tumor suppressor
gene, ZFN24, inhibits the development
of NSCLC by inhibiting the Wnt
signaling pathway to induce
cell senescence.
Front. Oncol. 12:1045516.
doi: 10.3389/fonc.2022.1045516

COPYRIGHT

© 2022 Frontiers Editorial Office. This is
an open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use,
distribution or reproduction is
permitted which does not comply
with these terms.

Retraction: A novel tumor suppressor gene, ZFN24, inhibits the development of NSCLC by inhibiting the Wnt signaling pathway to induce cell senescence

Frontiers Editorial Office*

KEYWORDS

ZNF24, non-small cell lung cancer (NSCLC), WNT signaling pathway, senescence, tumor suppressor genes (TSGs)

A retraction of the Original Research article

[A novel tumor suppressor gene, ZFN24, inhibits the development of NSCLC by inhibiting the Wnt signaling pathway to induce cell senescence](#)

by Pang B, Wang Y, and Chang X (2021). *Front. Oncol.* doi: 10.3389/fonc.2021.664369

The Publisher retracts the cited article.

Following publication, concerns were raised regarding the authorization and misinterpretation of some data used in this study. Specifically, during the investigation, which was conducted in accordance with Frontiers' policies, the authors failed to provide appropriate authorization for use of some of the original data. In addition, the Chief Editors of Frontiers in Oncology concluded that the article's conclusions were not sufficiently supported by the findings from the data provided. Given that unauthorized data use is a breach of Frontiers' guidelines, and that the Chief Editors expressed concern about the soundness of the conclusions, the article is being retracted.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors and authors' institution agree to this retraction.